NetworkNewsBreaks Evolus, Inc. (NASDAQ: EOLS) Featured in Mizuho Securities Research Report

NetworkNewsBreaks Evolus, Inc. (NASDAQ: EOLS) Featured in Mizuho Securities Research Report

Feb 07, 2020 (MENAFN via COMTEX) —

(MENAFN – Investor Brand Network) Evolus (NASDAQ: EOLS) was featured in a recent U.S. Equity Research Report published by Mizuho Securities USA LLC. The report reads, ‘Evolus is a commercial-stage biopharma company focused exclusively on the aesthetics market, with lead asset Jeuveau now approaching the one-year anniversary of its US launch. We are encouraged by the uptake of Jeuveau to date and, based on conversations with thought leaders and our Mizuho proprietary aesthetics market survey, we see significant room for upside as Jeuveau competes in one of the more attractive markets in biopharma. We also appreciate the legal overhang on the stock but our channel checks suggests Evolus/Daewoong should either prevail in the ongoing litigation or be able to settle for paying a reasonable royalty.’

To request access to the full report, visit

About Evolus, Inc.

Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau(R) (‘prabotulinumtoxinA-xvfs’), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure(TM) technology. Jeuveau(R) is powered by Evolus’ unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. For more information, visit the company’s website at .

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists

Read More Here...

Bookmark the permalink.

Comments are closed.